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Autophagy is a tightly regulated catabolic pathway that terminates in the lysosomal
compartment after the formation of a cytoplasmic vacuole that engulfs macromolecules
and organelles. Notably, autophagy is associated with several human pathophysiolog-
ical conditions, playing either a cytoprotective or cytopathic role. Many studies have
investigated the role of autophagy in cancer. However, whether autophagy suppresses
tumorigenesis or provides cancer cells with a rescue mechanism under unfavorable
conditions remains unclear. Mitochondria-associated membranes (MAMs) are juxtaposed
between the endoplasmic reticulum and mitochondria and have been identified as critical
hubs in the regulation of apoptosis and tumor growth. One key function of MAMs is to
provide asylum to a number of proteins with tumor suppressor and oncogenic properties.
Accordingly, mechanistic studies during tumor progression suggest a strong involvement
of these proteins at various steps of the autophagic process. This paper discusses the
present state of our knowledge about the intimate molecular networks between MAMs
and autophagy in cancer cells and addresses how these networks might be manipulated
to improve anticancer therapeutics.
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Cell Death and Autophagy
Cell death is a fundamental biological process that is highly evolutionarily conserved and occurs
in all multicellular organisms during the course of normal development and during adulthood.
Programmed cell death (PCD) is required to maintain tissue homeostasis, to remove abnormal or
damaged cells, and to remodel and sculpt tissues during morphogenesis (1, 2).
Perturbations to the normal patterns and regulation of cell death can contribute to several
pathologies, such as neurodegenerative diseases, autoimmune diseases, and cancer. Not surprisingly,
more than one form of cell death exists. Caspase-dependent apoptosis is considered the principal
pathway in mammals. However, various additional forms of cell death have been described more
recently and include necroptosis, pyroptosis, and autophagic cell death (3, 4).
Apoptosis andmacroautophagy (hereafter, referred to as autophagy) playmajor roles in determin-
ing cellular fate and are discrete cellular processes that are mediated by distinct groups of regulatory
and executioner molecules (4–6).
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Apoptosis is the best-described PCD mechanism and is char-
acterized by a series of morphological changes and plasma mem-
brane blebbing, leading to the formation of apoptotic bodies.
The molecular biology of apoptosis has been studied over the
last 40 years. The two most prominent molecular mechanisms
that regulate the cell death process are the extrinsic and intrinsic
pathways (7).
In the extrinsic pathway, the ligation of ligands (e.g., FasL,
also known as CD95L), tumor necrosis factor-α (TNF-α), TNF-
α-related apoptosis-inducing ligand (TRAIL, also known as
APO2L), or TNF-α ligand superfamily member 10 (TNFSF10),
with their respective death receptors, stimulate the recruitment
of adaptor proteins, such as Fas-associated via death domain
(FADD), which then recruits the initiator procaspase-8 or -10,
causing their dimerization and activation (8).
Unlike the extrinsic pathway that regulates apoptosis through
specialized death signals, the intrinsic pathway (also known as
“mitochondrial apoptosis”) is mediated by several intracellular
and extracellular signals, including endoplasmic reticulum (ER)
stress, loss of survival/trophic factors, toxins, radiation, hypoxia,
oxidative stress, ischemia–reperfusion injury, and DNA dam-
age. As a result, these signals converge on mitochondria
to induce mitochondrial outer membrane permeabilization
(MOMP), which contributes to multiple redundant lethal events,
including caspase cascades, the activation of caspase-independent
pathways for cellular dismantling and bioenergetic failure (9, 10)
via mitochondrial permeability transition pore opening (11). In
particular,MOMPproapoptotic factors (apoptogens) that are nor-
mally found in the intermembrane space (IMS) are irreversibly
released into the cytoplasm. A critical apoptogen that is released
from the intermembranemitochondria space is cytochrome c (Cyt
c). In the cytosol, Cyt c induces the apoptosis protease-activating
factor 1 (APAF-1) and ATP/dATP to assemble the apoptosome,
a molecular platform that promotes the proteolytic maturation
of caspase-9. Finally, caspase-9 recruits and activates effector
caspases.
Autophagy is a lysosome-mediated, multistep self-degradation
process and is distinct from other degradative pathways such as
proteasomal degradation, in which components are degraded to
supply energy (12, 13). During autophagy, an isolation membrane
sequesters a small portion of the cytoplasm, including cytosolic
materials and organelles, to form the autophagosome. Autophago-
somes fuse with lysosomes to yield autolysosomes, which degrade
internalized materials.
This process is executed and regulated by a large group of
distinct autophagy-related (Atg) proteins, which direct the four
major steps of the autophagic machinery: initiation, nucleation,
cycling, and expansion/closure. More than 30 Atg genes are
known. Readers interested in the specialized role of Atg proteins
should consult recent reviews (14–16). The cofactors involved in
autophagosome processing are described as follows. Upon induc-
tion of autophagy, the main negative regulator of the catabolic
process, MTOR (mechanistic target of rapamycin), is suppressed
and inactivated. This event activates the ULK1 (unc-51 like kinase
1)-complex (including ULK1, Atg13, FIP200, and Atg101), result-
ing in the ULK1-dependent phosphorylation of Atg13, FIP200,
and ULK1 itself and translocation of the complex to the ER, the
major site of autophagosome formation (17). At these activation
levels, ULK1 also regulates the activity of the class III phos-
phatidylinositol (PtdIns) 3-kinase complex (including Beclin1,
Atg14(L)/barkor, Vps15, Vps34, and Ambra1). This complex gen-
erates PI3P, which interacts with DFCP1, Atg2, and WIPI1, and
recruits other Atg proteins involved in membrane elongation.
Additionally, other complexes are fundamental for the autophago-
some elongation, such as two ubiquitin-like proteins. Atg7 and
Atg10 mediate the association of the Atg5–Atg12 complex with
Atg16L1. The Atg12–Atg5–Atg16L1 complex and the LC3 (Atg8
homolog)–phosphatidylethanolamine (PE) conjugate play impor-
tant roles in the elongation and closure of the isolation mem-
brane. The Atg12–Atg5–Atg16L1 complex is also required for
the formation of a covalent bond between LC3 and PE. When
autophagosome formation is concluded, the outer autophagoso-
mal membrane fuses with lysosomes, releasing autophagic cargo
into the lysosomal lumen (18).
Basal levels of autophagy are important formaintaining cellular
homeostasis. The physiological importance of autophagy inmain-
taining tissue homeostasis has been demonstrated in different
organs, including brain, liver, heart, muscle, kidney, and adipose
tissue (12, 19, 20). Nutrient deprivation is the main activator
for autophagy induction, but is not the only mechanism. For
example, decreased levels of specific amino acids and increased
levels of glucocorticosteroids and thyroid hormones also stimulate
the catabolic process (21). Furthermore, it is clear that autophagy
is an important energy generator. Indeed, amino acids obtained
by autophagy can be converted into intermediates of the tri-
carboxylic acid (TCA) cycle and contribute to ATP production.
The breakdown of lipid droplets by autophagy (i.e., lipophagy)
may also account for this energy-producing role, especially in
the liver (22). At molecular levels, nutrient failure modulates
the activity of important energy-sensing proteins. One of these
proteins is AMPK (50 AMP-activated protein kinase), a conserved
sensor of intracellular adenosine nucleotide levels. AMPK is acti-
vated when levels of AMP or ADP increase in response to slight
decreases in ATP production. This kinase is significantly involved
in autophagic regulation via mechanisms wherein MTOR activ-
ity is suppressed. Furthermore, MTOR regulates mitochondrial
ATP production and determines the health of the mitochondrial
population by a process termed mitophagy. Previous studies have
shown that these events are also regulated by AMPK-dependent
MTOR inactivation (23).
In addition, a function for autophagy in cell death has long
been proposed. Cell death is often attributed with high levels
of autophagosomes and active autophagy, and hence, the term
“autophagic cell death” is often used.
Many publications have reported that death stimuli in
mammalian cells and non-mammalian systems are caused by
autophagy (24). However, it is unclear whether autophagy occurs
prior to apoptosis or during the dismantling of cellular mecha-
nisms (25).
Furthermore, autophagy has been implicated in cell death
for various pathological conditions, such as neurodegeneration,
immunity, and aging and especially in cancer (26).
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Tumor-Suppressing and Tumor-Promoting
Roles of Autophagy in Cancer
Anumber of recent studies have revealed that autophagy can func-
tion as either a pro-death or pro-survival mechanism in cancer
cells. Depending on the different stages of tumor development and
the cell type, autophagy acts in two opposing capacities. During
early stages of cancer, autophagy has preventive effects; however,
after sufficient tumor development, cancer cells utilize autophagy
mechanisms to provide energy for sustained growth (Table 1).
The role of autophagy as a potent tumor suppressormechanism
was inferred from the observation that its molecular pathways
were frequently ablated in tumor cells.
During tumor initiation, autophagy is a protective process
that limits the accumulation of harmful proteins and organelles
through its intrinsic quality control activities. These tumor
suppressor properties are primarily attributed to protection
against genotoxic stress, such as the elimination of reactive
oxygen species (ROS) (27). Autophagy-mediated ROS removal
inhibits the deleterious effect of ROS on DNA mutations that
have been extensively shown to induce tumorigenesis (28).
Autophagy primarily prevents ROS accumulation through the
elimination of damaged mitochondria via a selective form of
autophagy (i.e., mitophagy) (29). The tumor-suppressing roles
of autophagy are also related to the regulation of the inflam-
matory process, which has been compared with the initiation of
cancer (30–32).
The role of autophagy in tumor suppression can also be
observed during the upregulation of members of the phos-
phatidylinositol 3-kinase (PI3K) family to similar levels as the
MTOR and AKT kinases (33, 34). These positive regulators
of cell growth inhibit PTEN (phosphatase and tensin homolog
deleted on chromosome 10) activity and other tumor suppres-
sors, such as LKB1 (liver kinase B1). These proteins are deregu-
lated in cancer cells and are potent activators of the autophagic
machinery (35).
Furthermore, AKT inhibits autophagy in an MTOR-
independent manner via the phosphorylation of the essential
autophagy and tumor suppressor protein BECLIN-1 (36). A
BECLIN-1 mutation has been shown to confer resistance to AKT-
dependent phosphorylation, increased autophagy, and inhibited
AKT-driven tumorigenesis (36). As for AKT, the implications
in cancer of the oncoprotein BCL (B-cell lymphoma)-2 and its
antiapoptotic homologs (e.g., BCL-XL and MCL-1) are attributed
to their regulatory roles in cell death and the autophagic process.
In particular, antiapoptotic BCL-2 family members have been
shown to suppress autophagy through their interaction with
or inhibition by BECLIN-1 (37, 38). Thus, the inhibition of
autophagy contributes to the transformation of a normal cell into
a cancerous cell and favors a state of genomic instability, i.e., the
ideal trigger for tumor initiation.
Another protagonist of this signaling pathway involving BCL-2
family members during autophagy is the putative tumor suppres-
sor AMBRA1 (autophagy/beclin-1 regulator 1), which is a crucial
factor in regulating autophagy in vertebrates. AMBRA-1 enhances
the activity of BECLIN-1, and thus mediates autophagosome
nucleation (39, 40).
TABLE 1 | Functions of autophagy in cancer.
Autophagy in tumor promotion Autophagy in tumor suppression
Tumor cells use autophagy to
adapt in a hypoxic environment
Contributes to cancer cells death at early
stage of several cancer types
Autophagy is activated as a
protective mechanism to mediate
the acquired resistance
phenotype of some cancer cells
during chemotherapy
Autophagy suppresses tumor initiation
limiting the accumulation of damaged
proteins and organelles such as mitochondria
and peroxisomes
Autophagy as a mechanism that
permits obtaining both ATP and
metabolic intermediates
Autophagy may protect against tumor
initiation and development by favoring cellular
differentiation, increasing protein catabolism,
or promoting autophagic cell death
BECLIN-1-mediated autophagy is negatively regulated through
a direct interaction between BECLIN-1 and ER-BCL-2. Past
studies have shown that the AMBRA-1-BECLIN-1 complex re-
localizes to the ER upon autophagy induction and that AMBRA-1
is able to bind to the antiapoptotic factor BCL-2 (41).
A further potentialmolecular link between defective autophagy
and tumorigenesis involves the autophagic-dependent protein
p62/SQSTM1, responsible for removing damaged organelles and
misfolded proteins that may cause DNA damage and genomic
instability. p62/SQSTM1 /  mice have been shown to be pro-
tected from RAS-induced lung carcinomas.
The predominant role of autophagy in tumor cells is to con-
fer stress resistance and thereby maintain cancer cell survival.
Indeed, tumor cells may use autophagy to increase the supply
of limited nutrients. In addition, autophagy has been induced
in hypoxic tumor cells distal from blood vessels, and cancer
cells have been shown to upregulate the autophagic process to
prevent metabolic stress induced by chemical and radiological
therapies. Based on these studies, there are a number of potential
anticancer approaches targeting the autophagic process. As such,
autophagy-modulating agents have been studied in preclinical
models (Table 2) (42).
In particular, the most promising anticancer agents are
autophagy inhibitors (such as chloroquine, CQ, and its deriva-
tive hydroxychloroquine, HCQ), which are able to enhance cell
cytotoxicity when combined with different anticancer drugs
(Table 3) (43). Interestingly, several studies have shown how
rapamycin and its analogs, i.e., allosteric MTOR inhibitors, in
combination with autophagy inhibitors (e.g., HCQ, bafilomycin
A1, and methyladenine) increased in vitro and in vivo cytotox-
icity of human cancers (44, 45). The efficacy of this combi-
nation may be explained as follows. The aberrant expressions
of PI3K/AKT/MTOR are found in several tumor types and are
important to the initiation and progression of cancers. These
cofactors are critical negative regulators of the autophagicmachin-
ery. When their activity or expression is blocked, autophagy
may be induced and may trigger consequent autophagic-related
resistance that promotes cancer cell survival. The resistance of
cancer cells to AKT/MTOR inhibitors is a significant issue in
a number of different tumor cells, such as relapsed mantle cell
lymphomas. Pretreatments with autophagic inhibitors can effec-
tively overcome this resistance by inhibiting AKT/MTOR activity,
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AMBRA-1 Negative BCL-2 family members
PML Unknown Regulate autophagy via ER-mitochondria
cross-talk (hypothetical)
PKCβ/p66Shc Negative PKCβ-dependent mitochondrial
translocation of p66Shc
p53 Negative Regulate autophagy via ER-mitochondria
cross-talk (hypothetical)
MFN-1/MFN-2 Positive PINK1/Parkin-dependent mitophagy
DRP1 Positive PINK1/Parkin-dependent mitophagy
HRAS Dual role Class I PI3K/AKT/MTOR pathway (negative),
Rac1/MKK7/JNK pathway (positive)
MTOR Negative Class I PI3K, AKT, PINK1
PP2A Positive MTOR, PML (hypothetical)
TABLE 3 |Some of the clinical trials combining the autophagy inhibitor HCQ.
Cancer type Drugs combination Phase trial
Breast cancer HCQ+ lixabepilone I/II
Pancreatic cancer HCQ+ gemcitabine I/II
Pancreatic cancer HCQ+ capecitabine+photon
radiation
II
Glioblastoma HCQ+ temozolomide I/II
Non-small-cell lung cancer HCQ+ cisplatin etoposide I/II
Non-small-cell lung cancer HCQ+paclitaxel and carboplatin II
Renal cell carcinoma HCQ+ high dose interleukin-2
and other systemic therapies
I
Metastatic colorectal cancer HCQ+ capecitabine, oxaliplatin,
and bevacizumab
II
Colorectal cancer HCQ+ FOLFOX/bevacizumab I/II
Ovarian cancer HCQ+ sorafenib I
Multiple myeloma HCQ+bortezomib I/II
Chronic myeloid leukemia HCQ+ imatinib II
blocking the autophagic process, and activating the apoptotic
pathway. The targeting of the PI3K/AKT/MTOR autophagy path-
ways can overcome cancer cell resistance to chemotherapy and
radiotherapy. However, the CQ and HCQ studies should be
interpreted carefully because the reported effects may be medi-
ated by mechanisms unrelated to autophagy inhibition. For
example, a recent study showed that a CQ treatment reduced
hypoxia and cancer cell metastasis and improved chemother-
apy efficacy rates and responses in an autophagic-independent
manner (46).
Recently, various cancer and autophagy-related factors, includ-
ing the aforementioned proteins, have been shown to localize at
mitochondria-associated ER membranes (MAMs), which are the
primary intracellular platforms that detect extracellular inputs and
stressful conditions (47, 48). We next discuss the roles of onco-
genes and oncosuppressors at MAMs in autophagy and consider
the structural functions of the ER-mitochondria interface in the
regulation of autophagy (49).
MAM Structure
MAMs are ERmembranes that are similar tomitochondria. How-
ever, MAMs are not simply static bridges between the ER and
mitochondria. On the contrary, interorganelle communication
between the ER and mitochondria is crucial for processes such as
lipid synthesis and transport, mitochondrial functions, the regu-
lation of calcium homeostasis, and apoptosis (48). A large number
of ER and mitochondria-associated proteins have been identified
in MAMs, demonstrating the crucial involvement of MAMs in
all physiological processes (Figure 1A). These proteins include
various chaperones [e.g., glucose-regulated protein 75 (Grp75)],
enzymes involved in ER redox regulation [e.g., ER oxidoreduc-
tase 1 alpha (Ero1α)] and protein kinases [e.g., ER stress sen-
sor double-stranded RNA-activated protein kinase (PKR)-like ER
kinase (PERK)]. Other proteins are also responsible for regulating
mitochondrial dynamics and morphology, such as the mitofusins
MFN-1 and MFN-2 and the dynamin-like protein DRP1 (50).
The ER is also the major site of Ca2+ storage in mammalian
cells. The movement of Ca2+ between the ER and mitochondria
is an essential component of the cell survival processes.
Several studies have examined the distribution ofCa2+ between
the ER and mitochondria (51–53). A study by Csordas and col-
leagues provided direct evidence for the existence of high-Ca2+
microdomains at ER-mitochondria contact sites that are regulated
by the area and gap width of ER-mitochondria interconnections.
Furthermore, they described a novel approach for determining the
[Ca2+]ER-mt in microdomains (54).
Based on these studies, MAMs regulate several Ca2+-
dependent cellular processes. The movement of Ca2+ between
the ER and mitochondria is essential for the correct execution
of both apoptotic (55) and autophagy pathways (56). Several
Ca2+ channels regulating the apoptotic program are located in
the MAM compartment. For example, IP3R3 (located at the ER)
and VDAC (situated at the outer mitochondrial membrane) are
highly concentrated in MAMs (57).
Furthermore, growing bodies of evidence shows that the ER-
mitochondria contact sites contribute to autophagosome forma-
tion and that proteins in the MAM compartments are indispens-
able for proper autophagic vesicle formation (49, 58–60).
MAMs, Novel Regulators of Cancer
Cell Fate?
Although the ER–mitochondria interface is known to assist the
autophagic pathway, the presumed link between the regulation of
the autophagy/MAMs axis and cancer progression has not been
addressed.
The role of MAMs in the regulation of apoptotic cell death in
cancer is partially understood. In particular, several proteins are
known to exert their pro- and antiapoptotic functions between the
ER and mitochondria (57) (Figure 1B).
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FIGURE 1 | Summary of the key functions of the ER-MAMs resident
proteins. (A) Several proteins reside in MAMs compartment and regulate the
juxtaposition between ER and mitochondria, including grp75, Ero1α, PERK,
and MFN-1/2. At the same time, other MAM resident proteins control the cell
survival by governing apoptosis (B) and autophagy (C). For example, it has
been reported that PML, IP3R3, and AKT mutually interact to allow the
correct Ca2+-movement between ER and mitochondria, an essential
proapoptotic signal. Interestingly, the maintenance of this interorganelle
Ca2+-communication is also important for the autophagic process. Of
relevance, reductions of mitochondrial Ca2+ accumulation may trigger
autophagy. In parallel, most of MAM proteins also govern the autophagic
machinery. Of relevance, AKT and MTOR regulate negatively autophagic
process. The same work is executed by the molecular axis composed by
p66Shc and PKCβ. It is widely accepted that autophagy is strictly linked to
several human diseases, in particular cancer. Think about a possible link
between autophagy, cancer, and MAMs is not so difficult. Several findings
may suggest this. For example, the corrected maintenance of MAMs integrity
by MFN-1/-2 and DRP1 is also crucial for autophagosome formation and
tumor cell growth. (D) The autophagic regulator AMBRA-1 has been found to
interact with both the oncogene BCL-2 and the tumor suppressor BECLIN-1.
Again, ER stress mediated by UPR a potent autophagic activator: at the
same time ER stress is a critical signal capable to drive cell death. Also, the
activity of the main proteins involved in Ca2+ release and reuptake at MAM
levels, SERCA and IP3R3, is reported to be involved in apoptosis and
tumorigenesis. Interestingly, the functioning of these channels is intimately
regulated by several oncogenes (like AKT) and tumor suppressor (such as
p53), which are also involved in regulation of autophagy. Abbreviations:
grp75, glucose-regulated protein 75; IP3R3, inositol 1,4,5-trisphosphate
receptor type 3; MFN-1/-2, mitofusin-1/-2; Hk2, Hexokinase 2; PACS,
phosphofurin acidic cluster sorting protein; VDAC, voltage-dependent
anion-selective channel; Ca2+, calcium; PGC-1α, peroxisome
proliferator-activated receptor gamma coactivator 1 alpha; PTEN,
phosphatase and tensin homolog; p66Shc, 66 kDa proto-oncogene Src
homologous-collagen homolog; PKCβ, protein kinase C beta; PP2a, protein
phosphatase 2; AKT, protein kinase B; SERCA, sarco/endoplasmic reticulum
Ca2+ ATPase; MTOR, mechanistic target of rapamycin; PML, promyelocytic
leukemia; UPR, unfolded protein response; PINK1, PTEN-induced putative
kinase 1; PERK, protein kinase-like ER kinase; DRP1, dynamin-related
protein; Ero1a, ER oxidoreductase 1 alpha; IP3R3, inositol
1,4,5-trisphosphate receptor type 3; AMBRA-1, Beclin1-regulated
autophagy; BCL-2, B-cell lymphoma 2; BECLIN-1, BCL-2-interacting
protein;, AMPK, 50 adenosine monophosphate-activated protein kinase).
Furthermore, most of these proteins possess tumor suppressor
and oncogenic properties and are mutated or deleted in various
types of human cancers.
One classical example is the tumor suppressor PML (promye-
locytic leukemia protein). This protein performs its proapoptotic
functions through the assemblage of nuclear macromolecular
structures called PML nuclear bodies (PML-NBs) (61). A recent
study found that this protein localizes to the ER and MAMs,
where it regulates Ca2+-dependent apoptosis by blocking the
activity of IP3R3 (62). PML is one component of a complex
composed of PP2A (protein phosphatase 2), IP3R3 (inositol 1,4,5-
trisphosphate receptor, type 3), and AKT. Several studies have
demonstrated that AKT mediates the phosphorylation of IP3R3
with a consequent decrease in Ca2+ transfer from the ER to the
mitochondria (63–65).
The significant accumulation of mitochondrial Ca2+ amplifies
the apoptotic signal. Key proteins (such as IP3R3, VDAC,
and the permeability transition pore-complex) have also been
demonstrated to be critical components for the ER-triggered,
proapoptotic mitochondrial membrane permeabilization
process (66).
Other tumor suppressors have also been observed to localize in
the MAM compartment and regulate Ca2+ flux and apoptosis by
regulating AKT activity.
In fact, PTEN was recently shown to interact with the
AKT/IP3R complex, leading to a reduction in its phosphorylation
and an increase in Ca2+ release (67).
In addition, the most studied tumor suppressor (p53) regulates
tumorigenesis via a Ca2+-dependent pathway. A recent study
found that p53 localizes to the ER andMAMs, where it modulates
the ER-mitochondria cross-talk and theCa2+ transfer from theER
to the mitochondria. As a result, mitochondria accumulate signif-
icant amounts of Ca2+, leading to an alteration in themorphology
of this organelle and the induction of apoptosis (68, 69).
Other indications of the close relationship between MAMs
and cell death can be found in the link between the SHC1 gene
(encoding for the p66Shc protein) and the putative oncogene
PRKCB (encoding for the protein kinase C, beta, PKCβ). p66Shc is
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a MAM protein (70) that is regulated by ROS and involved in the
regulation of Ca2+ homeostasis (71, 72). Once activated, p66Shc
translocates into mitochondria where it is reported to influence
the cell life span and apoptosis through the perturbation of mito-
chondrial functions. PKCβ is required for the phosphorylation
and activation of p66Shc at Ser36 and for its translocation into the
mitochondrial compartment (72).
One of the most mutated oncogenes in human cancer, H-RAS,
is localized inMAMs, where it exerts its antiapoptotic function by
modulating Ca2+-dependent apoptosis. Notably, the activation of
oncogenic H-RAS leads to a perturbation in Ca2+-handling and
dysfunction in mitochondrial physiology (73).
Intriguingly, these proteins are also known to regulate the
autophagic pathway. Thus, the localization of these players in
the MAM compartment could be important for the regulation of
autophagy (Figure 1C).
Okadaic acid (OA) is a PP2A-blocking drug. Several works have
identified a direct role for this compound in the regulation of
autophagy (74–76).
Interestingly, PML maintains an appropriate Ca2+ flux in the
MAM compartment by mediating the recruitment of PP2A (62).
Given that treatment with OA interferes with this molecular path-
way, PML may regulate autophagy via ER-mitochondria cross-
talk. The same issue is relevant to AKT. Several class I PI3K
inhibitors (such as LY294002 and wortmannin) negatively regu-
late autophagy through AKT inhibition (77). Preclinical studies
have also suggested the use of these compounds in cancer treat-
ment (78). The main inhibitor of the MTOR kinase, rapamycin,
was found to regulate AKT, and its use has been approved in
several clinical trials. Considering the important role of regulating
AKT activity to modulate cell death during cancer, the specific
and direct roles ofMAMcompartment-localized AKT needs to be
addressed (78). In addition, AKT may be directly phosphorylated
and activated by MTOR.
MTORalsomodulates the cellular distribution ofmitochondria
(79, 80) and the fate of this organelle when associated with the
MTOR complex 2 (MTORC2) (81). This complex is activated by
PINK1 (PTEN-induced kinase 1) (82), themain regulator of selec-
tive mitophagy (83). Interestingly, MTORC2 is also physically
associatedwithMAMs,where it interactswith andphosphorylates
AKT. Once activated, MTORC2-AKT signaling controls MAM
integrity, mitochondrial metabolism, and cell survival by regu-
lating the activity of MAM resident proteins PACS2, IP3R, and
HK2 (84).
Thus, these findings suggest a mutual regulation between
the MTORC2-AKT complex and the integrity and functionality
of MAMs. Moreover, the pharmacological modulation of this
MAM-localized complex could be used as a novel therapeutic
intervention to modulate cell fate in cancers with AKT/MTOR
mutations.
As reported earlier, the protein AMBRA-1 seems to be a fun-
damental regulator during autophagy induction, as evidenced
by its interactions with BCL-2 family members at the ER and
mitochondrial compartments.
Interestingly, several molecular and pharmacological agents
capable of interfering with BCL-2 activity (such as BH3-mimetic
compounds) are already used in cancer therapies (85). Thus,
these drugs may also modulate AMBRA-1 activities at the
ER–mitochondrial interfaces.
Several works report that a few of these chemotherapeutic
drugs modulate autophagy by regulating BCL-2 family member
activities (86), which shows a possible and crucial involvement of
AMBRA-1 protein activity in cancer therapies.
A growing body of evidence suggests the antidiabetic drug
metformin as a novel candidate for cancer therapy (87, 88). How-
ever, the mechanism of action remains unknown. This compound
drives mitochondrial bioenergetics, models the ER-mitochondria
contact site, and acts as a selective inhibitor of PKCβ (89, 90).
Because the role of p66Shc-PKCβ in the regulation of autophagy
has been recently shown (91) and metformin can be used to
manipulate the autophagic process (35, 92), metformin may also
directly affect the p66Shc-PKCβ-mediated regulation of the cell life
span at MAM sites.
A broad range of chemotherapeutic agents has been used
to improve or restore p53 activity (93). Given the autophagic-
modulating properties of this tumor suppressor and consider-
ing its novel apoptotic function in the ER-MAM compartment,
a novel therapy based on the simultaneous modulation of the
autophagic mechanism and the p53-dependent transfer of Ca2+
from the ER to mitochondria appears to be possible.
However, proteins with tumor suppressor and oncogenic prop-
erties are not the only proteins that have been linked to MAMs
and cancer progression. As reported earlier, a large number of
MAM proteins are required to maintain the proper communica-
tion channels between the ER and mitochondria. Most of these
proteins play pivotal roles during the autophagic process.
Notably, the correct assembly of MAMs is also guaranteed by
fusion and fission events in the mitochondrial compartment.
Mitochondrial fusion is primarily orchestrated by mitofusins-
1 and -2 (MFN-1/-2) and DRP1 (94). Remarkably, these pro-
teins are crucial for tethering the ER to the mitochondria and
stabilizing MAMs. Fusion proteins are critical elements for the
transfer of outermitochondrial membrane proteins to autophago-
somes (49). The proteins are also indispensable elements for
the execution of PINK1/Parkin-dependent mitophagy (95, 96).
Importantly, the modulation of MFNs and DRP1 activity has
been proposed to prevent tumor cell growth in several human
cancers (97). Mitochondrial biogenesis is a critical aspect of the
integrity of MAMs. Over the past few years, transcriptional coac-
tivators of the peroxisome proliferator-activated receptor gamma
coactivator-1 (PGC-1) family have been shown to directly medi-
ate the transcription of mitochondrial genes responsible for the
biogenesis of the organelle. This family includes PGC-1α and
PGC-1β, which are present in many cell types, including cells
found in the heart, skeletal muscles, and brain (98). Interest-
ingly, both isoforms were significantly upregulated in the chemo-
resistant cells. In particular, the silencing of PGC-1β isoform has
been shown to reestablish the sensitivity of cancer cells carry-
ing mtDNA mutations to chemotherapy agents (99). However,
activity of the alpha isoform has been linked to autophagic mod-
ulation (100). Thus, the action of PGC-1α may be modulated
by several pharmacological compounds (101), many of which
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FIGURE 2 |Modulation of the activity of ER-MAMs protein may
represent a novel therapeutical strategy against carcinogenesis.
MTOR, the main regulator of autophagic process, was found to modulate
MAMs structure and activities. In addition, other PI3K family members, like
AKT and PTEN, are located at ER-MAMs sites and represent critical
regulator of autophagy and MTOR activity. Of relevance, these PI3K family
members may be modulated by rapamycin and class I PI3K inhibitors.
Furthermore, since the interaction of AKT-PTEN axis with the tumor
suppressor PML and the protein PP2A at MAMs level is well described, it is
possible to hypothesize a pharmacological intervention at this level to
modulate the autophagic process during tumorigenesis. Also, the most
studied tumor suppressor, p53, recently found to be located at ER-MAMs
sites, was found to regulate autophagy. It is so clear that chemotherapic
agents activating p53 may exert their antitumor activities at ER-mitochondria
contact sites in an autophagy-dependent manner. Another critical regulator
of autophagy, AMPK, was recently found to destabilize the correct
juxtaposition between ER and mitochondria. Interestingly, the
pharmacological AMPK-activator Metformin is found to regulate the activity
of PKCβ. It is easy to think that metformin may interfere with the recent
discovered negative modulator of autophagy, the p66Shc–PKCβ axis.
Likewise, the potent autophagic regulator AMBRA-1 is found to be a potent
controller of BCL-2 family member activities. Interestingly, the employment of
BH3-mimetics is often used in chemotherapy, suggesting a possible role of
AMBRA-1 during therapeutical approaches against cancer. Finally, the most
important proteins involved in the mitophagic process, PINK1 and Parkin
interact and regulate the activity of different ER-MAMs resident protein, thus
suggesting the possibility of intercede to the activity of PINK-1-Parkin to
develop novel antitumor approaches. Abbreviations: MFN-1/-2,
mitofusin-1/-2; Hk2, hexokinase 2; PACS, phosphofurin acidic cluster
sorting protein; PGC-1α, peroxisome proliferator-activated receptor gamma
coactivator 1 alpha; PTEN, phosphatase and tensin homolog; p66Shc,
66 kDa proto-oncogene Src homologous-collagen homolog; PKCβ, protein
kinase C beta; PP2a, protein phosphatase 2; AKT, protein kinase B; SERCA,
sarco/endoplasmic reticulum Ca2+ ATPase; MTOR, mechanistic target of
rapamycin; PML, promyelocytic leukemia; PINK1, PTEN-induced putative
kinase 1; DRP1, dynamin-related protein; AMPK, 50 adenosine
monophosphate-activated protein kinase; PI3K, phosphoinositide-3-kinase;
AMBRA-1, Beclin1-regulated autophagy; BCL-2, B-cell lymphoma 2.
also regulate the autophagic machinery (such as AMPK activa-
tors). In addition, several works have reported that the disrup-
tion of PGC-1α expression could be a critical aspect of cancer
progression (102).
A functioning and healthy ER is a critical component of
the MAM integrity. When this aspect is lacking, ER stress
increases and results in unfolded protein response (UPR), ER-
associated degradation (ERAD), MAM structure alteration, and
Ca2+ release. For prolonged or extreme stresses, these signaling
pathways can lead to cell death (103). Accumulating data indicate
that ER stress is also a potent trigger of autophagy. Depending
on the context, autophagy counterbalances ER stress-induced ER
expansion enhances cell survival or commits the cell to non-
apoptotic death. In a cancerous environment, this subject is a
matter of debate. Previous reports have indicated that the inhi-
bition of autophagy in colon epithelial cells prevents cell death
induced by an ER-MAM stressor (e.g., Ca2+, thapsigargin, and
tunicamycin) (104). However, in other human cancers, certain
ER-MAM-disrupting treatments (e.g., photodynamic therapy and
vitamin D analog EB1089) may kill cancer cells by a mechanism
that depends on autophagy (105–107).
Overall, these findings suggest that the correct maintenance of
the ER-mitochondria interface is a critical part of the autophagic
process. Because catabolic process and several proteins linked
to MAMs are deeply involved in cancer progression, a number
of novel therapeutic approaches based on the manipulation of
MAMs can be proposed (Figures 1D and Figure 2).
Concluding Remarks
Half a century ago, Christian de Duve coined the term
“autophagy” to describe a process in which the cell digests its
cytoplasmic materials via lysosomal degradation.
More than 20 years ago, Jean Vance biochemically isolated an
intracellular structure representing the physical contact between
the ER and mitochondria and termed this membrane fraction
MAMs.
In the last decade, dysregulated autophagy has been associated
with various types of disease-like phenotypes, including cancer.
In recent years, it has been revealed that the function and
behavior of MAMs are central to the main molecular pathways
of human cells, and consequently, MAM dysfunction has been
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associated with several types of cancer. In addition, a growing
body of evidence suggests a key role for MAMs in the regulation
of autophagy.
Together, these findings suggest that the MAM environ-
ment could be a fundamental background for the regulation of
autophagic-dependent cancers. However, this intricate network
has not been well addressed.
Future work will be required to better understand how
this finely tuned compartment participates in various stages of
autophagy during cancer development. These studies will help
facilitate the rational design of combinatorial strategies aimed at
modulating autophagy or MAM structures and resident proteins
to elicit maximum therapeutic benefits against various types of
human cancers.
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